Tenax Therapeutics TENX 深 滬
等待開盤 09-30 09:30:00 美东时间
7.285
+0.025
+0.34%
華盛通- 最 高7.4427
- 今 開7.30
- 成交量 14.76万股
- 最 低 7.15
- 昨 收 7.26
- 總市值 3323.78万
- 52周最高 7.89
- 市盈率 靜 --
- 換手率 3.24%
- 52周最低 3.25
- 委 比 -91.49%
- 總股本 456.25万
- 歷史最高 274560.00
- 量 比 0.89
- 振 幅 4.03%
- 歷史最低 4.63
- 每 手 1
- 風險率 0.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
<p align="justify">Tenax Therapeutics announced that the European Patent Office has notified its intention to grant a patent for intellectual property protection of TNX-103 (oral levosimendan) and other formulations of levosimendan, including its active metabolites, for use in pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF). The patent, once granted, will provide protection in Europe through at leas...
09-16 11:00
Piper Sandler Initiates Coverage On Tenax Therapeutics with Overweight Rating, Announces Price Target of $20
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Overweight rating and announces Price Target of $20.
09-08 18:39
Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
Tenax Therapeutics, a Phase 3 pharmaceutical company, announced its participation in a fireside chat at the Cantor Global Healthcare Conference 2025, scheduled for September 4, 2025, in New York. CEO Chris Giordano and CMO Stuart Rich will discuss the Company’s novel cardiopulmonary therapies, including its work on levosimendan for PH-HFpEF, a prevalent form of pulmonary hypertension with no approved treatment to date. A live and archived webcast...
08-28 11:00
Guggenheim Maintains Buy on Tenax Therapeutics, Lowers Price Target to $14
Guggenheim analyst Seamus Fernandez maintains Tenax Therapeutics (NASDAQ:TENX) with a Buy and lowers the price target from $15 to $14.
08-14 21:36
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Tenax Therapeutics reported Q2 2025 financial results with $105.5M in cash and ongoing Phase 3 LEVEL study for TNX-103 in PH-HFpEF. Enrollment targeting 230 patients is expected to complete in H1 2026, with topline data in H2 2026. The company also plans to initiate the global Phase 3 LEVEL-2 study in 2025. R&D expenses rose to $6.1M, G&A to $5.7M, resulting in a net loss of $10.9M. Cash is projected to fund operations through 2027.
08-13 20:05
Tenax Therapeutics Approves Officer Exculpation Amendment
Tenax Therapeutics ( ($TENX) ) has shared an announcement. On June 11, 2025, Te...
06-18 05:11
Tenax Therapeutics Q1 EPS $(0.28) Misses $(0.19) Estimate
Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.19) by 47.37 percent. This is a 91.03 percent increase over losses of $(3.12) per share
05-15 04:12
Tenax Therapeutics Advances Cardiopulmonary Therapies
Tenax Therapeutics ( ($TENX) ) has released its Q4 earnings. Here is a breakdow...
04-25 11:56
Teanx Therapeutics plans secondary offering
Tenax Therapeutics (NASDAQ:TENX) filed a prospectus for resale by the selling stockholder of up to 378,346 shares of common stock and up to ~3.76M shares of common stock issuable upon the exercise of ...
04-16 14:57
Tenax Therapeutics announces $25M private placement
Tenax Therapeutics (NASDAQ:TENX) has entered into a securities purchase agreement for a private placement financing with RTW Investments, with total gross proceeds expected to be ~$25M. The private pl...
03-05 21:55
